The 6th project meeting of the 2D-BioPAD project took place on March 3-4, 2026, in Mannheim, Germany. Partners joined both in person and online to review progress and plan the next phase of the project. The meeting was hosted at the ZI premises.
During the meeting, partners presented the progress achieved during the fifth semester (October 2025 - March 2026). Updates covered several technical areas of the project, including aptamer selection for Alzheimer’s disease biomarkers, magnetic nanoparticle development, graphene materials, and biosensor technologies. The consortium reported progress in the development of both electrochemical and GFET biosensors, which will be used in the 2D-BioPAD diagnostic device.
Partners also presented updates on the integration of the biosensors into the device architecture, as well as preparations for the retrospective and prospective clinical pilot studies that will test the system with real plasma samples. Ethical approvals for the retrospective study have already been obtained, and the consortium is working on practical arrangements for sample benchmarking and shipment between partners.
The meeting also included discussions on communication, dissemination, and exploitation activities, including collaboration with other research initiatives and planning for future workshops and policy activities.
In the coming months, partners will focus on finalising key deliverables, testing biosensors with plasma samples, and continuing preparations for clinical validation. The next consortium meeting is planned for November 2026 in Kuopio, Finland, where partners will review progress and prepare for the project’s second review.
